Transcriptomic analysis of non-leukemic cell subsets in azacytidine-responsive AML highlights pathways associated with adhesion, platelet aggregation, and angiogenesis in mice and humans

Abstract Background Hypomethylating agents (HMAs), such as 5-azacytidine (AZA), are valuable treatment options for patients with acute myeloid leukemia (AML). Despite providing significant extensions in survival when used alone or in combination with BCL-2 inhibitors, resistance and eventual relapse...

Description complète

Détails bibliographiques

Auteurs principaux:	Nancy D. Ebelt, Suvithanandhini Loganathan, Lara C. Avsharian, Edwin R. Manuel
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-05-01
Collection:	Molecular Medicine
Sujets:	Acute myeloid leukemia 5-azacytidine Hypomethylating agents Remission Relapse Transcriptomics
Accès en ligne:	https://doi.org/10.1186/s10020-025-01233-2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!